Source comparison
Mechanism of Action — Central vs Peripheral Pathways
PT-141 differs from Viagra at the receptor level. Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone ( -MSH), binding to melanocortin receptors MC3R and MC4R primarily expressed in hypothalamic nuclei. When these receptors activate
This comparison does not assign a generated winner or score.
- PT-141 differs from Viagra at the receptor level. Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), binding to melanocortin receptors MC3R and MC4R primarily expressed in hypothalamic nuclei. When these receptors activate, they trigger dopaminergic and oxytocinergic signalling cascades. Neurotransmitter systems directly implicated in sexual motivation, reward anticipation, and arousal initiation. Animal models and Phase 2 human trials published in the Journal of Sexual Medicine demonstrate measurable increases in pro-sexual behaviours correlated with MC4R activation in the paraventricular nucleus of the hypothalamus. This is central nervous system modulation. It changes how the brain processes sexual stimuli before any peripheral arousal occurs.
- Viagra operates through PDE5 inhibition in vascular smooth muscle. Phosphodiesterase type 5 normally degrades cyclic guanosine monophosphate (cGMP), the molecule responsible for vasodilation in erectile tissue. By blocking PDE5, sildenafil allows cGMP to accumulate, prolonging smooth muscle relaxation and enhancing blood flow to the corpus cavernosum during sexual stimulation. This mechanism requires existing arousal. Nitric oxide release from endothelial cells in response to sexual stimulation is the trigger for cGMP production. Without that trigger, PDE5 inhibition achieves nothing. That's why Viagra doesn't create desire. It amplifies an existing physiological response.
- The clinical implication: PT-141 differs from Viagra in patient selection. Patients with low or absent libido due to hormonal disruption, SSRI-induced sexual dysfunction, or neurological conditions that blunt desire. Those populations don't respond to Viagra. Bremelanotide addresses the upstream problem. Conversely, patients with intact desire but impaired vascular function. Diabetic neuropathy, post-prostatectomy erectile dysfunction, age-related endothelial impairment. Those patients benefit from sildenafil's vascular mechanism. We've seen this repeatedly in clinical case reports: matching mechanism to patient profile determines therapeutic success.